Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes - PubMed (original) (raw)
Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes
J J Meier et al. Diabetes. 2001 Nov.
Abstract
In patients with type 2 diabetes, gastric inhibitory polypeptide (GIP) has lost much of its insulinotropic activity. Whether this is similar in first-degree relatives of patients with type 2 diabetes is unknown. A total of 21 first-degree relatives, 10 patients with type 2 diabetes, and 10 control subjects (normal oral glucose tolerance) were examined. During a hyperglycemic "clamp" (140 mg/dl for 120 min), synthetic human GIP (2 pmol. kg(-1). min(-1)) was infused intravenously (30-90 min). With exogenous GIP, patients with type 2 diabetes responded with a lower increment (Delta) in insulin (P = 0.0003) and C-peptide concentrations (P < 0.0001) than control subjects. The GIP effects in first-degree relatives were diminished compared with control subjects (Delta insulin: P = 0.04; Delta C-peptide: P = 0.016) but significantly higher than in patients with type 2 diabetes (P < or = 0.05). The responses over the time course were below the 95% CI derived from control subjects in 7 (insulin) and 11 (C-peptide) of 21 first-degree relatives of patients with type 2 diabetes. In conclusion, a reduced insulinotropic activity of GIP is typical for a substantial subgroup of normoglycemic first-degree relatives of patients with type 2 diabetes, pointing to an early, possibly genetic defect.
Similar articles
- Similar insulin secretory response to a gastric inhibitory polypeptide bolus injection at euglycemia in first-degree relatives of patients with type 2 diabetes and control subjects.
Meier JJ, Nauck MA, Siepmann N, Greulich M, Holst JJ, Deacon CF, Schmidt WE, Gallwitz B. Meier JJ, et al. Metabolism. 2003 Dec;52(12):1579-85. doi: 10.1016/s0026-0495(03)00327-5. Metabolism. 2003. PMID: 14669159 Clinical Trial. - Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes.
Meier JJ, Gallwitz B, Askenas M, Vollmer K, Deacon CF, Holst JJ, Schmidt WE, Nauck MA. Meier JJ, et al. Diabetologia. 2005 Sep;48(9):1872-81. doi: 10.1007/s00125-005-1863-7. Epub 2005 Jul 12. Diabetologia. 2005. PMID: 16010522 - Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: interactions with glucose, phenylalanine, and cholecystokinin-8.
Nauck M, Schmidt WE, Ebert R, Strietzel J, Cantor P, Hoffmann G, Creutzfeldt W. Nauck M, et al. J Clin Endocrinol Metab. 1989 Sep;69(3):654-62. doi: 10.1210/jcem-69-3-654. J Clin Endocrinol Metab. 1989. PMID: 2668324 - No evidence of tachyphylaxis for insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) in subjects with type 2 diabetes, their first-degree relatives, or in healthy subjects.
Nauck MA, Holle H, Kahle M, Tytko A, Deacon CF, Holst JJ, Meier JJ. Nauck MA, et al. Peptides. 2020 Mar;125:170176. doi: 10.1016/j.peptides.2019.170176. Epub 2019 Oct 25. Peptides. 2020. PMID: 31669136 Review. - Glucose-dependent insulinotropic polypeptide: effects on insulin and glucagon secretion in humans.
Christensen MB. Christensen MB. Dan Med J. 2016 Apr;63(4):B5230. Dan Med J. 2016. PMID: 27034187 Review.
Cited by
- Evaluating glucose-dependent insulinotropic polypeptide and glucagon as key regulators of insulin secretion in the pancreatic islet.
Lewandowski SL, El K, Campbell JE. Lewandowski SL, et al. Am J Physiol Endocrinol Metab. 2024 Jul 1;327(1):E103-E110. doi: 10.1152/ajpendo.00360.2023. Epub 2024 May 22. Am J Physiol Endocrinol Metab. 2024. PMID: 38775725 Review. - Characterizing Factors Associated with Excess Body Weight: A Descriptive Study Using Principal Component Analysis in a Population with Overweight and Obesity.
Fernández-Cardero Á, Sierra-Cinos JL, López-Jiménez A, Beltrán B, Cuadrado C, García-Conesa MT, Bravo L, Sarriá B. Fernández-Cardero Á, et al. Nutrients. 2024 Apr 12;16(8):1143. doi: 10.3390/nu16081143. Nutrients. 2024. PMID: 38674834 Free PMC article. - Pharmacological Advances in Incretin-Based Polyagonism: What We Know and What We Don't.
Novikoff A, Müller TD. Novikoff A, et al. Physiology (Bethesda). 2024 May 1;39(3):142-156. doi: 10.1152/physiol.00032.2023. Epub 2024 Feb 14. Physiology (Bethesda). 2024. PMID: 38353610 Review. - A Supportive Role of Mesenchymal Stem Cells on Insulin-Producing Langerhans Islets with a Specific Emphasis on The Secretome.
Sionov RV, Ahdut-HaCohen R. Sionov RV, et al. Biomedicines. 2023 Sep 18;11(9):2558. doi: 10.3390/biomedicines11092558. Biomedicines. 2023. PMID: 37761001 Free PMC article. Review. - GIPR rs10423928 and bone mineral density in postmenopausal women in Shanghai.
Zhang L, He J, Sun X, Pang D, Hu J, Feng B. Zhang L, et al. Endocr Connect. 2022 Feb 11;11(2):e210583. doi: 10.1530/EC-21-0583. Endocr Connect. 2022. PMID: 35029542 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous